TY - JOUR
T1 - New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis
AU - Naidu, Hemalatha
AU - Karagaiah, Priyanka
AU - Patil, Anant
AU - Yamauchi, Paul
AU - Kircik, Leon
AU - Grabbe, Stephan
AU - Goldust, Mohamad
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and improving symptoms. These therapeutic agents are administered according to disease severity. The improvement is assessed by the Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA), in which the appearance and extension of the lesions are taken into account. We searched for English-language literature regarding phase 2 and phase 3 trial drugs in the treatment of psoriasis in the following databases: PubMed, Scopus, Embase, Google Scholar, The Cochrane Library, and EBSCO, Clinicaltrials.gov. The keywords used include psoriasis, biologics, plaque psoriasis, systemic treatments, IL17 inhibitors, phase 2 trial, JAK inhibitor, and IL12/23 inhibitors. The search included only articles published in English.J Drugs Dermatol. 2022;21(8):826-831. doi:10.36849/JDD.6443.
AB - Psoriasis is known to have no definitive cure, which is in common with other inflammatory disorders. Various treatment options are available, and they help in decreasing the disease activity and improving symptoms. These therapeutic agents are administered according to disease severity. The improvement is assessed by the Psoriasis Area and Severity Index (PASI) and Investigator Global Assessment (IGA), in which the appearance and extension of the lesions are taken into account. We searched for English-language literature regarding phase 2 and phase 3 trial drugs in the treatment of psoriasis in the following databases: PubMed, Scopus, Embase, Google Scholar, The Cochrane Library, and EBSCO, Clinicaltrials.gov. The keywords used include psoriasis, biologics, plaque psoriasis, systemic treatments, IL17 inhibitors, phase 2 trial, JAK inhibitor, and IL12/23 inhibitors. The search included only articles published in English.J Drugs Dermatol. 2022;21(8):826-831. doi:10.36849/JDD.6443.
UR - http://www.scopus.com/inward/record.url?scp=85136339884&partnerID=8YFLogxK
U2 - 10.36849/JDD.6443
DO - 10.36849/JDD.6443
M3 - Article
C2 - 35946976
AN - SCOPUS:85136339884
SN - 1545-9616
VL - 21
SP - 826
EP - 831
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 8
ER -